Praxis Precision Medicines PRAX 深 滬
已收盤 07-02 16:00:00 美东时间
318.52
-1.080
-0.34%
華盛通- 最 高329.2686
- 今 開319.82
- 成交量 35.83万股
- 最 低 310.10
- 昨 收 319.60
- 總市值 88.80亿
- 52周最高 366.52
- 市盈率 靜 --
- 換手率 1.29%
- 52周最低 37.19
- 委 比 -40.00%
- 總股本 2787.88万
- 歷史最高 914.265
- 量 比 0.36
- 振 幅 6.00%
- 歷史最低 11.85
- 每 手 1
- 風險率 116.89%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines granted 951 restricted stock units to five new non-executive employees under its 2024 Inducement Plan on July 1, 2026. The awards, granted as inducements for employment, will vest in four equal annual installments. The company focuses on CNS precision neuroscience, translating genetic insights into therapies for CNS disorders.
07-02 20:01
分析师解读医疗健康企业：Praxis Precision Medicines（PRAX）与波士顿科学（BSX）
多家分析师近期针对美股医疗健康板块两家公司发布最新评级，涉及标的为精准医疗企业Praxis Precision Medicines（PRAX）与医疗器械企业波士...
06-30 20:48
分析师对多家医疗保健企业观点分歧 涉及Outlook Therapeutics（OTLK）、Praxis Precision Medicines（PRAX）与默沙东（MRK）
近期多家机构分析师对医疗健康板块3只个股发布最新评级及目标价，涉及标的为OTLK、PRAX、MRK。 OTLK：BTIG分析师朱利安·哈里森给出持有评级，目标...
06-30 20:48
美股大行评级 | 康托·菲茨杰拉德大幅上调AMD、英特尔、迈威尔科技、美光、西部数据目标价！Applied、INIO、LFTO、Quantinuum获多家大行首予买入评级
今日重点评级关注：Evercore ISI集团：维持ProQR Therapeutics"跑赢大市"评级，目标价从5美元升至6美元；摩根士丹利：维持霍尼韦尔"标配"评级，目标价从245美元升至490美元
06-30 10:14
Praxis sees encephalopathies asset relutrigine action date extended
The US FDA has extended the review period for Praxis Precision Medicines' (PRAX) application for relutrigine for SCN2A and SCN8A developmental and epileptic encephalopathies by three months to Dec. 27...
06-30 06:14
Applied Materials To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Keybanc raised the price target for Applied Materials Inc (NASDAQ:AMAT) from $550 to $750. Keybanc analyst Ste...
06-29 21:05
Needham Maintains Buy on Praxis Precision Medicine, Raises Price Target to $575
Needham analyst Ami Fadia maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target from $537 to $575.
06-29 18:35
Praxis Wins FDA Breakthrough Status for Elsunersen Epilepsy Drug
Praxis Precision Medicines ( ($PRAX) ) just unveiled an announcement. On June 2...
06-23 05:50
Praxis' Seizure Drug Move Towards Faster Development After Positive Trial Results
Praxis Precision Medicines Inc. (NASDAQ:PRAX) said on Monday that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation to elsunersen (PRAX-222), its investigational therapy for seizures associated with SCN2A developmental and epileptic encephalopathy (SCN2A-DEE) caused by g...
06-23 01:27
RBC Capital Initiates Coverage On Praxis Precision Medicine with Outperform Rating, Announces Price Target of $449
RBC Capital analyst Leonid Timashev initiates coverage on Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform rating and announces Price Target of $449.
06-18 21:43
